Davis J. E. sold $1.9M of DGX
Davis J. E. (CEO and President) sold 10,000 shares of QUEST DIAGNOSTICS INC (DGX) at $194.14 ($1.94M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may influence short-term sentiment among traders who track insider flows, but the 10b5-1 designation generally lowers the probability of a fundamental read-through.
Market read
A disclosed insider sale in DGX; likely more relevant for sentiment/positioning than for fundamentals.
What to watch
The filing does not indicate whether additional tranches remain under the same 10b5-1 plan, nor does it provide context on the executive’s broader compensation/hedging activity.
Background
SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/President under a pre-arranged 10b5-1 plan.
Ticker impact
Quest Diagnostics CEO and President Davis J. E. sold 10,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any impact is more likely short-term and sentiment-driven.
The filing is a routine insider disclosure and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.
Market effects
Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.
None indicated.
None indicated.
Counterpoint
10b5-1 sales can be purely mechanical; the sale may not reflect bearish fundamentals and could be offset by other insider buys or institutional activity not shown here.
Key entities
- issuerQuest Diagnostics Inc
DGX, the company whose shares were sold by its CEO/President.
- insiderDavis J. E.
CEO and President who executed the sale under a 10b5-1 plan.
